Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma

Inclusion Criteria: * Participant diagnosed with KHE with or without KMP * Participant age 0-12 years * Participant with detailed medical records of the disease at the time of screening * Participant with at least two years of remission of KHE and no previous toxicity or adverse events * Participant with normal liver and kidney function * Participant with signed and dated informed consent from the guardian(s) Exclusion Criteria: * Participant with other hematological diseases * Participant with other solid tumor * Participant with general disease such as hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney dysfunction, and cardiopulmonary insufficiency. * Participant with infectious diseases * Unwilling participant